Investigators at University of Texas MD Anderson Cancer Center Describe Findings in Antineoplastics (Venetoclax Consolidation In High-risk Cll Treated With Ibrutinib for ≥1 Year Achieves a High Rate of Undetectable Mrd).

Houston, State:Texas, United States, North and Central America, Antineoplastics, BCL-2 Inhibitors, Drugs and Therapies, Ibrutinib Therapy, Kinase Inhibitors, Pharmaceuticals, Protein Kinase Inhibitors, Venetoclax Therapy Keywords: Houston; State:Texas; United States; North and Central America; Antineoplastics; BCL-2 Inhibitors; Drugs and Therapies; Ibrutinib Therapy; Kinase Inhibitors; Pharmaceuticals; Protein Kinase Inhibitors; Venetoclax Therapy EN Houston State:Texas United States North and Central America Antineoplastics BCL-2 Inhibitors Drugs and Therapies Ibrutinib Therapy Kinase Inhibitors Pharmaceuticals Protein Kinase Inhibitors Venetoclax Therapy 1200 1200 1 10/30/23 20231103 NES 231103 2023 NOV 3 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Data detailed on Drugs and Therapies - Antineoplastics have been presented. [Extracted from the article]